MENGENAI EPISOD INI
Cancer immunotherapy research continues to evolve and offers patients a transformative alternative to traditional therapies. Anette Briendl, Senior Science Editor at BioWorld, talks about the current research landscape for immunotherapies. Learn about the challenges and potential of emerging therapies that are being developed, including the importance of checkpoint inhibitors and Car T-cells, to improve patient outcomes and how her work has provided incredible insight into developments in the immuno-oncology space.
Bahasa Inggeris
Inggeris
TRANSKRIP 🔗
Are you the producer of this podcast?
Add a podcast transcript
Need Audio-to-Text?
Transcribe with Listen411 in Just 60 Seconds
EPISOD LAIN DALAM PODCAST INI
Immuno-oncology therapies have opened up the most promising frontiers in cancer treatment today. But, with drug development costs increasing, how is it possible to maintain commercial viability?
Peter Winter, Editor at BioWorld, talks about challenges to commercial viability in the immuno-onco ...
Recently, the U.S. Patent and Trademark Office’s released a dataset that contained over 250,000 records, included patent applications and granted patents; the USPTO was interested in the insights this data could reveal to guide cancer research. Di Cross, Director of Research at Clarivate A ...
Join Chris Willis, Manager of Discovery and Translational Sciences at Clarivate Analytics, as he talks about immuno-oncology, why it is promising for cancer patients and how it continues to evolve. Learn more about the new approved drugs on the market that treat indications of cancer and the way ...
The recent buzz around CRISPR-Cas9, a genome editing tool, has revolved around its potential for treating various genetic diseases, including cancer. Jack Hopwood, Intellectual Property Consultant and Bertrand Sautier, Strategic Account Manager at Clarivate Analytics talk about how research acti ...
Penafian: Podcast dan karya seni yang dibenamkan pada halaman ini adalah daripada Clarivate Analytics – Formerly the IP&Science business of Thomson Reuters, yang merupakan hak milik pemiliknya dan tidak bergabung dengan atau disokong oleh Listen Notes, Inc.
SUNTING
Terima kasih kerana membantu memastikan pangkalan data podcast dalam keadaan terkini.
